On September 8, 2020 Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, reported that it will provide a corporate update at the 22nd HC Wainwright Annual Global Investment Conference (Press release, Lipocine, SEP 8, 2020, https://www.prnewswire.com/news-releases/lipocine-to-participate-in-hc-wainwright-annual-global-investment-conference-301124187.html [SID1234564784]). The conference will take place virtually September 14 – 16, 2020.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details:
Date:
Monday, September 14
Time:
12 noon Eastern Time
Webcast:
To register in advance for the conference, refer to View Source